Monitor SEC filings for the prospectus supplement to assess offering size, pricing, and dilution impact. Given RVPH's small market cap ($14M), even a modest offering could result in significant dilution if priced near current levels.
Price Chart
Executive Summary
Reviva Pharmaceuticals (RVPH) announced plans for a public offering of common stock and warrants, with proceeds intended to fund its Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia and general corporate purposes. The offering size, pricing, and terms have not been disclosed, and completion is subject to market conditions.
Key Facts
- Reviva Pharmaceuticals is conducting a public offering of common stock (or equivalents) and warrants.
- All securities are being offered by the company; no selling shareholders mentioned.
- A.G.P./Alliance Global Partners is the sole placement agent.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine, R&D, and general corporate purposes.
- Offering will be made under an effective shelf registration (Form S-3, filed Feb 2024), with a preliminary prospectus supplement to be filed.
- No specific offering size, price, or number of shares disclosed; terms subject to market conditions.
Financial Impact
Dilutive to existing shareholders once priced and completed; magnitude unknown pending final terms.
Risk Factors
- Potential for substantial dilution if offering is large relative to current market cap or priced at a discount.
- Equity offering in a weak market environment may depress stock price ahead of and after pricing.
- No assurance the offering will be completed due to market or regulatory conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Press Release | $0.3521 $0.3521 | · 0.00% | ▲ +1.75% | $0.5000 (+42.01%) |
Jul 10, 2026 12w ago | 25-NSE | $0.6200 $0.4775 | ▲ +22.98% | ▲ +25.40% | $0.5000 (+19.35%) |
May 13, 2026 20w ago | Press Release | $0.3900 $0.6839 | ▼ −75.36% | ▼ −76.22% | $0.5000 (−28.21%) |
May 13, 2026 20w ago | 8-K | $0.3521 $0.7600 | ▼ −115.85% | ▼ −116.46% | $0.5000 (−42.01%) |
Apr 15, 2026 24w ago | 8-K | $0.8900 $0.8000 | ▼ −10.11% | ▼ −16.16% | $0.5000 (−43.82%) |
Mar 30, 2026 26w ago | Press Release | $0.6600 $0.8800 | ▲ +33.33% | ▲ +20.74% | $0.5000 (−24.24%) |
Mar 19, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▼ −2.41% | ▲ +5.21% | $0.5000 (+39.76%) |
Mar 18, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▲ +2.41% | ▼ −5.21% | $0.5000 (−39.76%) |
Mar 5, 2026 30w ago | 8-K | $4.20 $0.7200 | ▼ −82.86% | ▼ −79.07% | $0.5000 (−88.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access